Table 1.
TAU | TCT | p | |
---|---|---|---|
Sample size | 22 | 24 | 0.75 |
Age | 35.73 (13.00) | 34.54 (12.13) | 0.55 |
Gender: Males | 9 (41% | 13 (54%) | 0.61 |
Hispanic | 6 (27%) | 4 (17%) | |
Race | |||
African American | 3 (14%) | 5 (21%) | 0.51 |
Asian | 2 (9%) | 1 (4%) | |
Caucasian | 12 (55%) | 13 (54%) | |
More than one race | 5 (23%) | 3 (12%) | |
Native American | 0 (0%) | 2 (8%) | |
Education | 11.95 (2.17) | 11.71 (1.99) | 0.69 |
Illness duration | 15.23 (12.78) | 16.12 (13.67) | 0.82 |
Chlorpromazine equivalents | 982.534 (758.10) | 1329.42 (972.78) | 0.82 |
SAPS | 5.36 (5.02) | 6.46 (4.26) | 0.62 |
SANS | 13.09 (3.41) | 12.96 (4.19) | 0.22 |
Days to follow-up | 99.30 (24.26) | 89.44 (19.79) | 0.2 |
Hours of training | 27.97 (10.20) |